![Sample our Behavioral Sciences journals, sign in here to start your access, latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/110801/TOC-Subject-Sample-2021-Behavioral-Sciences.jpg"})
Abstract
Objective. Brain iron deficiency has been supposed to be involved in the pathophysiology of ADHD. Available studies assessing iron in ADHD are based on serum ferritin, a peripheral marker of iron status. To what extent serum ferritin correlates with brain iron (BI) is unclear. The main aim of this study was to compare BI, estimated with magnetic resonance imaging (MRI) in the putamen, pallidum, caudate, and thalamus, between children with and without ADHD. The secondary aim was to assess the correlation between serum ferritin and BI levels. Methods. Thirty-six children (18 with and 18 without ADHD, the latter including nine healthy controls and nine psychiatric controls) completed MRI and blood sampling. Brain iron levels were estimated by imaging T2*. Results. Children with ADHD showed significantly lower estimated BI in right and left thalamus compared to healthy controls. Estimated BI did not differ significantly between children with ADHD and psychiatric controls. Children with ADHD had significantly lower levels of serum ferritin than healthy as well as psychiatric controls. Serum ferritin and T2* values did not correlate significantly in most regions. Conclusions. Low iron in the thalamus may contribute to ADHD pathophysiology.
Acknowledgments
None.
Statement of Interest
Dr Cortese has received financial support to attend medical meetings from Eli Lilly & Company and Shire Pharmaceuticals, and has been co-investigator in studies sponsored by GlaxoSmithKline, Eli Lilly & Company, and Genopharm. He serves as a consultant for Shire Pharmaceuticals.
Dr Lecendreux has received research funding from Shire. He has served as a consultant for UCB and Shire Pharmaceuticals. He has served as an investigator for Eli Lilly & Company and Shire Pharmaceuticals.
Dr Chechin is employed by Philips Healthcare.
Dr Konofal has served on advisory boards for Shire Pharmaceuticals and UCB. He has consulted for Shire Pharmaceuticals. He has served as a medical writer for Remidica and Janssen-Cilag. He has served on the speaker's bureau of UCB and served as a principal investigator in clinical trials supported by Eli Lilly & Company and Janssen-Cilag.
Drs Azoulay, Castellanos, Chalard, Sebag, Sbarbati, Delorme, Mouren, and Dalla Bernardina report no competing interests.